Ironwood Pharmaceuticals ... (IRWD)
NASDAQ: IRWD
· Real-Time Price · USD
1.39
0.12 (9.45%)
At close: Sep 26, 2025, 3:59 PM
1.47
5.76%
After-hours: Sep 26, 2025, 07:51 PM EDT
Ironwood Pharmaceuticals Revenue Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Collaborative arrangements revenue Revenue | 2.9M | 800K | 892K | 413K | 419K | 368K | 432K | 121K | 91K | 151K | 144K | 148K | 192K | 114K | 219K | 200K | 100K | 300K | 200K | 200K |
| Collaborative arrangements revenue Revenue Growth | +262.50% | -10.31% | +115.98% | -1.43% | +13.86% | -14.81% | +257.02% | +32.97% | -39.74% | +4.86% | -2.70% | -22.92% | +68.42% | -47.95% | +9.50% | +100.00% | -66.67% | +50.00% | 0.00% | n/a |
| Royalty Revenue | 900K | 373K | n/a | 700K | 200K | 516K | 400K | 107.38M | 580K | 570K | 365K | 409K | 480K | 396K | 547K | 408K | n/a | n/a | n/a | n/a |
| Royalty Revenue Growth | +141.29% | n/a | -100.00% | +250.00% | -61.24% | +29.00% | -99.63% | +18414.14% | +1.75% | +56.16% | -10.76% | -14.79% | +21.21% | -27.61% | +34.07% | n/a | n/a | n/a | n/a | n/a |
| Collaborative arrangement, collaboration and license agreements Revenue | 428K | n/a | n/a | 222K | 358K | n/a | 755K | n/a | 104.06M | 107.2M | 108.64M | 97.23M | 97.53M | 116.99M | 103.75M | 103.39M | n/a | n/a | n/a | n/a |
| Collaborative arrangement, collaboration and license agreements Revenue Growth | n/a | n/a | -100.00% | -37.99% | n/a | n/a | n/a | n/a | -2.93% | -1.32% | +11.73% | -0.31% | -16.63% | +12.76% | +0.35% | n/a | n/a | n/a | n/a | n/a |
| Collaborative arrangement, other agreements Revenue | 87K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Collaborative arrangement, other agreements Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Europe And Other Revenue | 904K | 811K | 1.72M | 807K | 833K | 706K | 431.81M | 714K | 731K | 700K | 597K | 861K | 609K | 582K | 702K | 668K | 731K | 550K | 605K | 721K | 423K | 550K | 603K |
| Europe And Other Revenue Growth | +11.47% | -52.93% | +113.51% | -3.12% | +17.99% | -99.84% | +60377.73% | -2.33% | +4.43% | +17.25% | -30.66% | +41.38% | +4.64% | -17.09% | +5.09% | -8.62% | +32.91% | -9.09% | -16.09% | +70.45% | -23.09% | -8.79% | n/a |
| North America Revenue | 86.42M | 39.39M | 181.27M | 89.43M | 92.15M | 72.45M | n/a | 110.73M | n/a | n/a | 679K | n/a | n/a | n/a | 765K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| North America Revenue Growth | +119.39% | -78.27% | +102.71% | -2.96% | +27.19% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 16.8M | 24.26M | 33.59M | 36.11M | 36.96M | 37.6M | 37.57M | 32.35M | 52.48M | 31.12M | 28.39M | 28.62M | 30.12M | 28.86M | 28.69M | 27.74M | 27.05M | 27.65M | 33.98M | 34.93M | 34.64M | 36.45M | 39.19M | 40.92M | 43.25M | 64.74M | 58.18M | 55.25M | 68.36M | 61.92M | 57.95M | 61.77M | 57.79M | 55.6M | 55.21M | 44.99M | 36.92M | 36.17M | 31.51M | 30.44M | 32.95M | 30.35M |
| Selling, General, and Administrative Revenue Growth | -30.77% | -27.78% | -6.99% | -2.30% | -1.70% | +0.10% | +16.14% | -38.37% | +68.67% | +9.61% | -0.80% | -5.00% | +4.38% | +0.61% | +3.41% | +2.55% | -2.17% | -18.63% | -2.71% | +0.82% | -4.96% | -6.99% | -4.23% | -5.38% | -33.20% | +11.28% | +5.31% | -19.18% | +10.40% | +6.85% | -6.19% | +6.89% | +3.93% | +0.72% | +22.72% | +21.86% | +2.07% | +14.79% | +3.51% | -7.63% | +8.60% | n/a |
| Research and Development Revenue | 23.37M | 27.43M | 25.39M | 29.83M | 30.39M | 25.82M | 35.06M | 32.98M | 1.13B | 12.85M | 10.45M | 11.54M | 11.45M | 10.82M | 31.85M | 10.91M | 12.16M | 15.48M | 16.27M | 21.69M | 22.08M | 28.03M | 26.54M | 27.55M | 28.76M | 53.99M | 44.27M | 46.79M | 38.93M | 36.51M | 40.12M | 37.06M | 37.34M | 33.7M | 38.44M | 37.53M | 31.68M | 31.84M | 27.63M | 25.83M | 28.65M | 26.64M |
| Research and Development Revenue Growth | -14.80% | +8.04% | -14.87% | -1.85% | +17.71% | -26.38% | +6.30% | -97.07% | +8657.11% | +22.98% | -9.52% | +0.81% | +5.82% | -66.02% | +192.02% | -10.33% | -21.45% | -4.81% | -25.01% | -1.74% | -21.23% | +5.61% | -3.68% | -4.20% | -46.73% | +21.95% | -5.39% | +20.19% | +6.65% | -9.00% | +8.23% | -0.75% | +10.81% | -12.33% | +2.44% | +18.45% | -0.50% | +15.26% | +6.96% | -9.84% | +7.53% | n/a |